



SECOND-QUARTER 2025 RESULTS

TOTAL COMPANY

\$11.1B

SALES
WORLDWIDE

+7.5%¹

Organic* sales growth for
underlying base business**

\$1.26²

ADJUSTED DILUTED EPS

KEY BUSINESS UNITS



\$5.4B

MEDICAL DEVICES



\$2.2B

DIAGNOSTICS



\$1.4B

ESTABLISHED
PHARMACEUTICALS



\$2.2B

NUTRITION

FULL-YEAR 2025 GUIDANCE³

\$5.10 to \$5.20

ADJUSTED DILUTED EPS

7.5% to 8.0%

Organic* sales growth for the
underlying base business**

BUSINESS HIGHLIGHTS

EXPANDING OUR STRUCTURAL HEART PORTFOLIO

- ▶ FDA approval for Abbott's Tendyne™ transcatheter mitral valve replacement (TMVR) system.
- ▶ First-of-its-kind device to help treat people with mitral valve disease.



PIONEERING LEADLESS CARDIAC PACING

- ▶ The AVEIR™ Conduction System Pacing clinical feasibility study marks the world's first evaluation of a leadless pacemaker delivering conduction pacing.
- ▶ Technology closely replicates the heart's natural rhythm, offering a novel treatment option for patients with irregular heartbeats.



ADVANCING HEART RHYTHM MANAGEMENT

- ▶ Completed enrollment in FlexPulse U.S. IDE trial to evaluate the TactiFlex™ Duo Pulsed Field Ablation System.
- ▶ System designed to treat patients with heart rhythm disorders such as atrial fibrillation.



¹Organic sales growth excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect® product line in the Nutrition business. For full financial data and reconciliation of non-GAAP measures, please see our press release dated July 17, 2025, available at www.abbottinvestor.com.
²Excludes the impact of COVID-19 testing sales.

³On a GAAP basis, second-quarter Abbott sales increased 7.4%. ²Second-quarter 2025 GAAP diluted EPS was \$1.01. ³Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2024, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.